Navigation Links
Orexigen Therapeutics to Present at Upcoming Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:
February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:
February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Corporate Contacts: OrexigenOrexigen

MediaJay Hagan

Denise PowellChief Business Officer

WCG(858) 875-8673

(510)
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Smith & Nephew (LSE:SN, NYSE: SNN ... its entry into the forefoot market with the ... Comprised of three separate repair options, the HAT-TRICK ... and reconstruction, a metatarsal osteotomy guide, and a ... also known as hammer toe correction. ...
(Date:7/31/2014)... July 31, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... JOLLA, Calif. , July 30, 2014 ... ), a biopharmaceutical company leading the discovery and development ... will report financial results and highlights for the quarter ... after the U.S. financial markets close. ... Wednesday, August 6, 2014, at 5:00 pm Eastern Daylight ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... Computing researchers at Houston,s Rice University and electronics ... announced the formation of a $2.6-million Institute for ... at 4 million Singapore dollars, aims to slash ... -- special-purpose computer chips that power everything from ...
... Presented at the 12th World Conference on Lung ... 4 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... two cohorts of,the Phase I part of a ...
... 4 The Cytokine Institute (TCI), a Los,Angeles-based ... the opening of a new office in the ... measures and analyzes the effects of,chemical and toxic ... Boston-based consulting arm, Green Reach Consulting, TCI now ...
Cached Biology Technology:Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2
(Date:7/31/2014)... make a rational choice to be liberal or conservative? ... a matter of genetics?, Two political scientists from the ... say that neither conscious decision-making nor parental upbringing fully ... right. , A growing body of evidence shows that ... of political differences, the researchers say in the latest ...
(Date:7/31/2014)... the U.S. surgeon general issued a 101-page report about ... University published a paper breaking new ground on how ... responds when exposed to ultraviolet (UV) light. , The ... UV rays found in sunlight. This damage can lead ... , "Our paper advances foundational knowledge about how ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
Breaking Biology News(10 mins):Scientists find growing consensus: Political attitudes derive from body and mind 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... This press release is available in French ... a whole lot safer for consumers, thanks to Concordia University ... substances in dairy and other products. "Even though Canada ... antibiotics in cows, until now there were no methods or ...
... basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist ... at the Institut de recherches cliniques de Montral (IRCM), and ... patents awarded to the institute and covering different uses of ... Schiller,s laboratory at the IRCM. A total of ...
... OAK RIDGE, Tenn. -- A tree outside Oak Ridge ... inspiration for a discovery that may ultimately lead to ... more. Just as a breeze causes leaves, branches ... the molecular level perform hundreds of chemical processes that ...
Cached Biology News:Discovery of therapeutic peptides affecting mitochondria 2ORNL fundamental discovery casts enzymes in new light 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: